HK1093308A1 - Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock - Google Patents

Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock

Info

Publication number
HK1093308A1
HK1093308A1 HK06114161.8A HK06114161A HK1093308A1 HK 1093308 A1 HK1093308 A1 HK 1093308A1 HK 06114161 A HK06114161 A HK 06114161A HK 1093308 A1 HK1093308 A1 HK 1093308A1
Authority
HK
Hong Kong
Prior art keywords
sub
moiety
shock
treatment
peptide
Prior art date
Application number
HK06114161.8A
Other languages
English (en)
Inventor
Peter Petzelbauer
Kai Zacharowski
Original Assignee
Fibrex Medical Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0108704A external-priority patent/AT414097B/de
Priority claimed from AT0004005A external-priority patent/AT501263B1/de
Application filed by Fibrex Medical Res & Dev Gmbh filed Critical Fibrex Medical Res & Dev Gmbh
Publication of HK1093308A1 publication Critical patent/HK1093308A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06114161.8A 2004-06-25 2006-12-27 Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock HK1093308A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0108704A AT414097B (de) 2004-06-25 2004-06-25 Pharmazeutische zubereitung zur behandlung von schock
AT0004005A AT501263B1 (de) 2005-01-13 2005-01-13 Pharmazeutische zubereitung zur behandlung von schock
PCT/AT2005/000228 WO2006000007A1 (de) 2004-06-25 2005-06-24 Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock

Publications (1)

Publication Number Publication Date
HK1093308A1 true HK1093308A1 (en) 2007-03-02

Family

ID=35058593

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06114161.8A HK1093308A1 (en) 2004-06-25 2006-12-27 Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock

Country Status (20)

Country Link
US (1) US20080249006A1 (es)
EP (1) EP1691827B1 (es)
JP (1) JP2008503503A (es)
AT (1) ATE439856T1 (es)
AU (1) AU2005256121B2 (es)
BR (1) BRPI0506148A (es)
CA (1) CA2544676A1 (es)
CY (1) CY1109631T1 (es)
DE (1) DE502005007926D1 (es)
DK (1) DK1691827T3 (es)
EA (1) EA008799B1 (es)
ES (1) ES2331958T3 (es)
HK (1) HK1093308A1 (es)
HR (1) HRP20090618T1 (es)
IL (1) IL173969A (es)
NZ (1) NZ545634A (es)
PL (1) PL1691827T3 (es)
PT (1) PT1691827E (es)
SI (1) SI1691827T1 (es)
WO (1) WO2006000007A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502987A1 (de) * 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
ES2371038T3 (es) * 2006-02-23 2011-12-26 Fibrex Medical Research & Development Gmbh Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.
US8067533B2 (en) 2006-02-23 2011-11-29 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP2193370A2 (en) * 2007-09-24 2010-06-09 Fibrex Medical Research & Development GmbH Methods of screening for compounds having anti-inflammatory activity
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US7884074B2 (en) 2008-05-15 2011-02-08 Ikaria Development Subsidiary Two, LLC Compounds and methods for prevention and/or treatment of inflammation using the same
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
JP4181874B2 (ja) * 2000-12-12 2008-11-19 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
ATE345788T1 (de) * 2001-03-06 2006-12-15 Dorian Bevec Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
ES2371038T3 (es) * 2006-02-23 2011-12-26 Fibrex Medical Research & Development Gmbh Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.

Also Published As

Publication number Publication date
ES2331958T3 (es) 2010-01-21
AU2005256121A8 (en) 2008-08-21
NZ545634A (en) 2009-09-25
ATE439856T1 (de) 2009-09-15
BRPI0506148A (pt) 2006-10-24
PL1691827T3 (pl) 2010-01-29
EP1691827B1 (de) 2009-08-19
DE502005007926D1 (de) 2009-10-01
WO2006000007A1 (de) 2006-01-05
HRP20090618T1 (hr) 2010-01-31
SI1691827T1 (sl) 2010-01-29
PT1691827E (pt) 2009-11-23
CA2544676A1 (en) 2006-01-05
US20080249006A1 (en) 2008-10-09
IL173969A0 (en) 2006-07-05
CY1109631T1 (el) 2014-08-13
JP2008503503A (ja) 2008-02-07
EP1691827A1 (de) 2006-08-23
IL173969A (en) 2011-06-30
DK1691827T3 (da) 2009-12-14
AU2005256121B2 (en) 2011-03-03
AU2005256121A1 (en) 2006-04-27
EA200600561A1 (ru) 2006-08-25
EA008799B1 (ru) 2007-08-31

Similar Documents

Publication Publication Date Title
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
UA84432C2 (ru) Очищенные пептиды и соединения, которые их содержат
EP2261246A3 (en) Binding polypeptides for B-lymphocyte stimulator protein (BLyS)
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2009004315A8 (en) Isolated peptides and uses thereof
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
MXPA03005218A (es) Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico.
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
UA91497C2 (ru) ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА
NO20040905L (no) Peptidaktige forbindelser som selektivt binder til P-selektin, farmasoytiske preparater som inneholder peptidforbindelsene og nukleinsyrer som koder for dem.
ATE485831T1 (de) Behandlung von neurodegeneration
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
HK1083850A1 (en) Peptides binding the phosphatase 2a protein and polynucleotides encoding same
WO2005087809B1 (en) Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2007020405A3 (en) Integrin i-domain binding peptides
EP1724346A3 (de) An die Lck-SH3 und Hck-SH3 Domäne bindende Peptide
NZ591989A (en) Prion-specific peptide reagents
ECSP003720A (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130624